Where it comes from
- Made in
- Made from angiotensin III by aminopeptidase N, in brain, kidney and vessels
- Sent out by
- Follows the shorter angiotensins
- Acts on
- Hippocampus
- Kidney vessels
- Endothelium
What it does
- Improves learning and memory when given into the brain of a rat 2
- Raised kidney cortical blood flow in rats, though later work reports the opposite
- Raises PAI-1 in endothelium, which is the one effect with a plausible route to thrombosis
In medicine
- No medicine and no test. Its binding site turned out to be an enzyme rather than a classical receptor, which changed how the whole AT4 literature is read 1
- Because IRAP sits inside the cell and trims other peptides too, what an angiotensin IV analogue actually does is harder to state than for a receptor drug 1
- It is not measured in practice: these fragments are too short-lived and too close in mass for a routine assay
Beyond the body’s own use
- Given into the brain of a rat it improves spatial learning, and the effect has held up across laboratories. That is the whole basis of the memory claim 2
- IRAP inhibitors and angiotensin IV analogues are studied for memory loss in animals. None has reached a human trial, and no medicine has come of it 1
- The reported effect on kidney blood flow has gone both ways in different rat studies, which is a fair warning about how firm any of this is
Sources
This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.